Researchers conducted a systematic review and meta-analysis to understand survival outcomes for older adults with blood cancers who received haploidentical hematopoietic stem cell transplants (HSCT). This type of transplant uses stem cells from a partially matched donor, often a family member. The analysis combined data from 16 studies involving 1,268 patients aged 60 and older.
The review found that the pooled two-year overall survival rate was 53%, meaning just over half of patients were alive two years after transplant. The three-year survival rate was 45%. At three years, about 28% of patients had died from causes other than cancer returning, and about 32% experienced a relapse of their cancer.
It's important to note that survival outcomes varied significantly between different studies included in this review. The two-year survival rates ranged from as low as 15% to as high as 74% across different research centers. This substantial variation means the average numbers may not predict what any individual patient might experience.
This analysis combines existing observational studies and cannot determine whether this transplant approach causes better or worse outcomes compared to other treatments. The results provide a broad picture of what has been reported in the literature, but patients should discuss their specific situation with their medical team when considering treatment options.
